FluxMPS™ CMRL 1066 Medium: 1X Liquid

FluxMPS™ CMRL 1066 Medium: 1X Liquid

FluxMPS™ CMRL 1066 Medium: 1X Liquid is a Microfluidics Suitable, ultra-filtered cell culture medium engineered for organ-on-a-chip (OoC), tissue-on-a-chip (ToC), and microphysiological system (MPS) applications. A quadruple-stage train (0.1 µm ×2 + 0.04 µm ×2) reaches a 0.04 µm final cut-off, five times finer than the 0.22 µm membranes used for conventional sterile filtration.

• Quadruple-stage nano-filtration: 0.1 µm (Prefiltration I & II) + 0.04 µm (Final filtration I & II — Polish)
• Endotoxin release specification: < 0.05 EU/mL (USP <85> BET)
• CMRL 1066 basal formulation with 2200 mg/L sodium bicarbonate, 1000 mg/L glucose, and 100 mg/L L-glutamine; pH 7.4 (USP <791>)
• Prepared with Ultrapure Type 1 water (18.2 MΩ·cm)
• Manufactured under an ISO 13485:2016 quality management system; aseptic fill & finish (ISO Class 5 / Class 100)
• Mycoplasma risk mitigated by 0.1 µm mycoplasma-retentive filtration (not tested per lot)
• Custom formulations available — pH, glucose, salts, HEPES, and nutrient composition on request

Engineered where standard media fails

Conventional 0.22 µm-filtered media carry mycoplasma-sized particulates (0.2–0.3 µm), subvisible debris, and variable endotoxin loads that accumulate inside microchannels — corrupting biosensor readings and shortening device lifetimes. FluxMPS™ is built to address these failure modes at the filtration stage.

Quadruple-stage filtration system

FluxMPS™ CMRL 1066 Medium: 1X Liquid is processed through a validated four-stage filtration train reaching a 0.04 µm final pore size — addressing mycoplasma-scale particulates and subvisible debris that 0.22 µm filtration cannot remove.

1. 1

   0.1 µm Prefiltration I

   Removes large particulates, cell debris, and protein aggregates; protects the first 0.04 µm cartridge.

2. 2

   0.04 µm Final filtration I

   First 0.04 µm pass; retains sub-micron particulates and microaggregates, including mycoplasma-scale particles (0.2–0.3 µm) that pass a 0.22 µm filter.

3. 3

   0.1 µm Prefiltration II

   Second dedicated prefilter, protecting the second 0.04 µm cartridge from residual particulate load.

4. 4

   0.04 µm Final filtration II — Polish

   Ultimate polishing filter; aseptic fill & finish performed in a validated ISO Class 5 (Class 100) laminar-flow workstation.

Designed for next-generation cell culture platforms

FluxMPS™ CMRL 1066 Medium: 1X Liquid is intended for use across organ-on-a-chip, metabolic research, live-cell imaging, and primary cell models where particulate load and endotoxin variability are of concern.

Automated Bioreactors & Robotics

An optional 0.01 µm (10 nm) ultra nano-filtered MPS Grade variant is available for automated bioreactor and robotic perfusion systems requiring the tightest particulate exclusion. This is a separate product tier from the 0.04 µm Microfluidics Suitable formulation described above.

• Total Particulate Exclusion: 0.01 µm filtration for nanoscale valve and sensor protection
• Valve & Sensor Protection: reduces particulate-related blockage risk in precision fluidic systems
• Extended Perfusion Stability: supports flow rate consistency across multi-week automated runs

Inquiry Required: The MPS Grade 0.01 µm variant is available by special order. Contact support@diagnocine.com to request this variant.

Lot-release quality parameters

Every production batch of FluxMPS™ CMRL 1066 Medium: 1X Liquid undergoes the quality-release battery listed below before shipment.

Full composition (mg/L)

Complete formulation with CAS numbers, reproduced from the manufacturer specification. Custom compositions available on request.

ISO 13485:2016 manufacturing & compliance

FluxMPS™ CMRL 1066 Medium: 1X Liquid is manufactured under a full ISO 13485:2016 quality management system, with final packaging, testing, and customization completed at Diagnocine Precision in Totowa, New Jersey, USA.

How DCP-CMRL1X (FluxMPS™) compares

Side-by-side comparison against conventional 0.22 µm-filtered alternatives of the same base formulation.

Comparison figures from published supplier specifications, accessed 2 September 2026. Suppliers that publish no numeric endotoxin specification are shown as “Not specified.”

Frequently asked questions

Common questions about FluxMPS™ CMRL 1066 Medium: 1X Liquid and Microfluidics Suitable cell culture media.

Supporting literature

Peer-reviewed publications supporting the scientific rationale for Microfluidics Suitable ultra-filtered media and microfluidic cell culture applications.

1. Huh D et al. (2010). Reconstituting organ-level lung functions on a chip. Science, 328(5986), 1662–1668. doi:10.1126/science.1188302
2. Bhatia SN & Ingber DE (2014). Microfluidic organs-on-chips. Nature Biotechnology, 32(8), 760–772. doi:10.1038/nbt.2989
3. Bhattacharya S et al. (2018). Challenges in maintaining cell viability during microfluidic experiments. Electrophoresis, 39(7), 997–1006. doi:10.1002/elps.201700375
4. Warburg O (1956). On the origin of cancer cells. Science, 123(3191), 309–314. doi:10.1126/science.123.3191.309
5. Emmons EV (1965). Detection of mycoplasma in cell cultures using filtration. Proceedings of the Society for Experimental Biology, 118, 1010–1015. doi:10.3181/00379727-118-29988
6. Kim S et al. (2012). Gut-on-a-chip microdevice replicates key functional features of the human intestine. Lab on a Chip, 12(12), 2165–2174. doi:10.1039/c2lc40074j
7. Zhang YS et al. (2017). Multisensor-integrated organs-on-chips platform for automated and continual in situ monitoring of organoid behaviors. PNAS, 114(12), E2293–E2302. doi:10.1073/pnas.1612906114
8. Vernetti L et al. (2017). Functional coupling of human microphysiology systems. Scientific Reports, 7, 42296. doi:10.1038/srep42296
9. Schuster B et al. (2020). Automated microfluidic platform for dynamic and combinatorial drug screening of tumor organoids. Nature Communications, 11, 5271. doi:10.1038/s41467-020-19058-4
10. Zheng F et al. (2021). Organ-on-a-chip systems: microengineering to biomimic living systems. Small, 17(7), 2004175. doi:10.1002/smll.202004175